Physician profile
Opal C Flowers
NPI 1023873247
$1,571.48
in general payments reported to CMS, 2019-2025
18 companies · $903 in 2025
The $903 reported for 2025 was more than what 86% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $68.07 · 2024: $600 · 2025: $903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,571.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $265.52 | 2024-2025 | Uptravi, Opsumit, Opsynvi |
| Alnylam Pharmaceuticals INC. | $215.47 | 2024-2025 | Amvuttra |
| Lexicon Pharmaceuticals, INC. | $164.08 | 2024 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.61 | 2024-2025 | Jardiance |
| United Therapeutics Corporation | $101.36 | 2024-2025 | Remodulin, Orenitram, Remodulin |
| Pfizer INC. | $94.41 | 2024-2025 | |
| Baxter Healthcare | $93.32 | 2025 | Starling System |
| Novo Nordisk INC | $92.82 | 2024-2025 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $84.72 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $63.30 | 2024-2025 | Wainua, Farxiga |
| Bridgebio Pharma, INC. | $60.51 | 2025 | Attruby |
| Novartis Pharmaceuticals Corporation | $50.82 | 2024-2025 | |
| Paragonix Technologies, INC. | $34.54 | 2024-2025 | Sherpapak, Lungguard, Liverguard |
| Merck Sharp & Dohme LLC | $34.39 | 2025 | Winrevair |
| Cvrx, INC. | $33.62 | 2024-2025 | Barostim Neo System |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $32.75 | 2025 | Camzyos |
| Scpharmaceuticals INC. | $23.55 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.69 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Opal Flowers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.